British Reporter — Altered microbiome, sleep deprivation, increase in alcohol consumption among possible culprits in 30-year global trend
More
British Reporter — First major study to investigate dairy consumption and cancer risk in Chinese adults has found that greater intake was associated with higher risks of liver cancer and female breast cancer, according to university of Oxford.
More
British Reporter — A Merseyside man has become the first in the UK to receive a ‘vaccine’ that is hoped will stop his recurring head and neck cancer from returning – in a clinical research trial which may help bring further ground-breaking
More
British Reporter — Scientists from the University of Oxford and the Ludwig Institute for Cancer Research are building on the success of the Oxford-AstraZeneca vaccine against SARS-CoV-2 to develop a vaccine to treat cancer. Researchers have designed a two-dose therapeutic cancer vaccine
More
British Reporter — Researchers aim to develop tiny robotic sensors to detect bowel cancers, the second most common cause of cancer death in the UK. Armed with cutting edge terahertz imaging, the sensors could be used in colonoscopies or even to detect skin
More
The FINANCIAL -- Postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer that has spread to a limited number of lymph nodes, and whose recurrence risk is relatively low, do not benefit from chemotherapy when it
More
The FINANCIAL -- The global pandemic of the coronavirus disease, called COVID-19, continues to have a serious impact on many people, including cancer patients, their families, and caregivers. State and local authorities, as well as health officials, continue to adjust
More
The FINANCIAL — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that the China National Medical Products Administration (NMPA) has approved XTANDI® (enzalutamide soft capsules) for the treatment of adult men with non-metastatic castration-resistant prostate cancer (nmCRPC) with high
More
The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior
More
The FINANCIAL — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic
More